Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA209-8KX Phase I/II study of subcutaneous nivolumab with or without rHuPH20
2023-503554-12-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label trial of nivolumab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma and 3 more (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Serum nivolumab PK parameters (Parts A, B, D, E) and Serum nivolumab trough concentration (Part C). Started Jun 2023; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)melanomahepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-503554-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503554-12-00.